Pharmaceutical company Granules on Tuesday said the US FDA has concluded an audit of its arm Granules Consumer Health’s packaging facility in Manassas, Virginia. The US FDA issued Zero 483s to Granules Consumer Health (GCH), it added.
The packaging site was inspected by the US FDA between March 15-20, 2023, Granules said in a statement.
“The audit is a pre-approval inspection for three products filed from the facility. The packaging site strengthens our proposition to control the value chain and provides us with the agility needed in a very dynamic OTC space,” said Priyanka Chigurupati, Executive- Director, Granules USA, Inc. & Granules Pharmaceuticals.
The packaging facility in Manassas is spread over 79,000 sq ft and has several packaging suites to service customer needs, the pharmaceutical company added.
Granules Consumer Health claims that its packaging facility will enable it to service leading retailers more effectively.
The company reported its Q3 earnings in January. It witnessed a surge of over 23% in its profit to Rs 124.3 crore against Rs 100.9 crore in the same quarter last year. The company also saw an improvement in its margin, which came in at 20.18% as opposed to 17.4% in the same quarter last year.
Last month, Granules received US FDA ANDA nod for Losartan Potassium tablets USP. Losartan Potassium tablets are used to treat hypertension.
The stocks of Granules India were trading at Rs 287.40 apiece, up nearly 2% at 2:00 pm.
(Edited by : Sangam Singh)
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Over 50 onion farmers detained in Nashik ahead of PM Modi's visit
May 16, 2024 11:14 AM
Why Google CEO is cautiously optimistic about the election year
May 16, 2024 9:51 AM
Mark Mobius reveals how markets will react if NDA wins 400+ Lok Sabha seats
May 15, 2024 8:09 PM